GlaxoSmithKline
GlaxoSmithKline (GSK) is a multinational pharmaceutical and biotechnology company based in London, England. GSK, founded in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham, is the world's tenth-largest pharmaceutical company and ranks #294 on the 2022 Fortune Global 500, trailing China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck.
The business created the first malaria vaccine (RTS,S), which it said in 2014 will be accessible for 5% above cost. Several GSK legacy medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine, are on the World Health Organization's List of Essential Medicines.
The company is a constituent of the FTSE 100 Index and has its principal listing on the London Stock Exchange. It has a market value of £70 billion as of August 2022, making it the ninth largest on the London Stock Exchange. It is also listed on the New York Stock Exchange.
GlaxoSmithKline is a global biopharmaceutical company that aims to bring science, technology, and talent together to fight disease. GlaxoSmithKline's goal is to improve the health of 2.5 billion people by the end of 2030. The high objectives of GlaxoSmithKline for patients are reflected in promises to growth and a step-change in performance.
Founded: 2000
Headquarters: London, England, UK
Website: https://www.gsk.com/en-gb/
